Skip to main content
. 2023 Feb 15;13(2):452–463.

Figure 6.

Figure 6

The combination of BR101801 and Venetoclax has a significant synergistic antitumor effect. A. GI50 of BR101801, ibrutinib, and idelalisib for the SU-DHL-6 cell line. In vitro anti-cancer effects of BR101801 were confirmed in various cell lines. B. In vitro synergy effect of the combination of with BR101801 and Venetoclax. SU-DHL-6 cells were treated with BR101801 (100 nM), ibrutinib (100 nM), idelalisib (100 nM), or/and Venetoclax (10 nM) for 24 h. C. Comparison of the effects of BR101801 and Venetoclax as a monotherapy and combination therapy. DOHH-2 xenografts were treated with BR101801 (50 mg/kg, PO, QD) and/or Venetoclax (100 mg/kg, PO, QD). D. The antitumor effect of BR101801 and Venetoclax combination therapy in a late-stage tumor model. DOHH-2 xenografts were treated with a combination of BR101801 (50 mg/kg, PO, QD), with Venetoclax (100 mg/kg, PO, QD). E. Schematic showing the mechanism of action of BR101801 in DLBCL. Data are presented as the mean ± S.D. (*P < 0.05, **P < 0.01, and ***P < 0.001).